This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Michael Piepkorn, MD, PhD; Martin A. Weinstock, MD, PhD; Raymond L. Barnhill, MD

Arch Dermatol. 1997;133(8):995-1002.

Abstract
Nearly a century of clinical inquiry has failed to incontrovertibly resolve the question of whether elective lymph node dissection is therapeutically beneficial in the management of clinically localized melanoma. The controversy has been renewed by a recent interim update from the Intergroup Melanoma Surgical Program, sponsored by the National Cancer Institute, which has indicated a small survival benefit in a narrowly defined subgroup of patients with primary melanoma. That report stimulated this review of the data, which are presented in the historical context that originally prompted the Intergroup study. Case selection bias has intractably hindered firm conclusions from the numerous nonrandomized studies of elective lymphadenectomy. The two original randomized trials that were executed during the 1970s failed to uncover any significant effect of the procedure on survival. Definitive conclusions from the recent Intergroup report are limited by the likelihood that the observed therapeutic benefits are a chance occurrence resulting from uncorrected multiple subgroup comparisons. It remains uncertain whether elective lymphadenectomy can be therapeutically beneficial in the management of melanoma. Nevertheless, it is clear that the procedure, or preferably sentinel lymphatic mapping with selective lymphadenectomy, can provide clinically relevant prognostic information, as well as the staging data requisite to adjuvant interferon alfa-2b therapy or enrollment into other adjunctive trials for patients at high risk of clinical relapse.

Arch Dermatol. 1997;133:995-1002

Author Affiliations
From the Departments of Medicine and Pathology, University of Washington School of Medicine, Seattle (Dr Piepkorn); the Dermatoepidemiology Unit, Veterans Affairs Medical Center, and Department of Dermatology, Brown University, Providence, RI (Dr Weinstock); and the Dermatopathology Division, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass (Dr Barnhill).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Elective Lymph Node Dissection for Melanoma Laid to Rest Yet Again
Ready and Weinstock
Arch Dermatol 2003;139:1203-1204.
FULL TEXT  

Elective Lymph Node Dissection in Patients With Melanoma: Systematic Review and Meta-analysis of Randomized Controlled Trials
Lens et al.
Arch Surg 2002;137:458-461.
ABSTRACT | FULL TEXT  

Tumor Vascularity, Proliferation, and Apoptosis in Human Melanoma Micrometastases and Macrometastases
Barnhill et al.
Arch Dermatol 1998;134:991-994.
ABSTRACT | FULL TEXT